Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair-deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study Meeting Abstract
| Authors: | Rojas, C.; Eskens, F.; Ghiringhelli, F.; Özgüroglu, M.; Caglevic, C.; Gumus, M.; Tosi, D.; Grenier, J.; Gonzalez, A. F.; Arenas, A.; Gonzalez-Cortijo, L.; Robinson, A. G.; Cuello, J.; Bell, M. C.; Kwiatkowski, M.; Sendur, M. A. N.; Liu, Q.; Keenan, T. E.; Healy, J. A.; Guo, R. |
| Abstract Title: | Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair-deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557401352 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.5502 |
| Notes: | Meeting Abstract: 5502 -- Source: Wos |
